C12Y 301/02015
Ubiquitin thiolesterase
Official title: Ubiquitin thiolesterase (3.1.2.15)
C12Y301/02015 (Ubiquitin thiolesterase) appears on 12 US grants and 33 published applications in this corpus.
Search patents in C12Y- Granted patents
- 12
- Published applications
- 33
- Assignees
- 12
- Inventors
- 48
- Latest grant
- 10 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 3 |
| 2004 | 0 | 0 |
| 2005 | 2 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 3 |
| 2016 | 0 | 1 |
| 2017 | 1 | 1 |
| 2018 | 0 | 5 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 2 | 4 |
| 2022 | 0 | 2 |
| 2023 | 0 | 1 |
| 2024 | 3 | 1 |
| 2025 | 0 | 3 |
By publication year. Applications have been published since 2001.
Recent patents
- Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L110 Dec 2024US 12,163,958 B2Abbott Laboratories
- Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)1 Oct 2024US 12,105,098 B2Abbott Laboratories
- Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers24 Sep 2024US 12,099,069 B2Abbott Laboratories
- Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)1 Jun 2021US 11,022,617 B2Abbott Laboratories
- Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L125 May 2021US 11,016,092 B2Abbott Laboratories
- Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l117 Apr 2025US 2025/0123279 A1Abbott Laboratories
- Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)16 Jan 2025US 2025/0020666 A1Abbott Laboratories
- Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers16 Jan 2025US 2025/0020672 A1Abbott Laboratories
- Immune enhancers9 May 2024US 2024/0150810 A1Deutsches Krebsforschungszentrum
- Methods and systems of diagnosing brain injury17 Aug 2023US 2023/0258661 A1
Most cited
By later US patents
- Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers8US 10,877,048 B2Abbott Laboratories · 2020
- Modulation of drug resistance via ubiquitin carboxy-terminal hydrolase8US 5,932,422 AMillennium Pharmaceuticals, Inc. · 1999
- Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)7US 11,022,617 B2Abbott Laboratories · 2021
- Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L16US 11,016,092 B2Abbott Laboratories · 2021
- 68999, a human ubiquitin carboxyl-terminal hydrolase family member and uses therefor2US 6,900,044 B2Millennium Pharmaceutical, Inc. · 2005